i remember we recommended it hard at 80 when david pyott came on. he's allergan's ceo. the consolidation is hot and heavy and you have to earn some in the industry if you want to beat the market even though we'd normally be selling pharmaceutical stocks now that the economy's heating up. i expect many acquisitions in this space in the next 90 days. fifth place is another takeover called pep co. it got a bid if excelon. we have way too many utilities it periodically you will hear there will be consolidation and i've been saying that since 1984. the only real consolidator is excelon and that said, i'm a huge believer that we're riding a wave of mergers and acquisitions in it country that's the biggest in history. nothing can be ruled out. the number six is vertex. >> we it's because of companies like vertex that are working on breakthrough drugs that we do not know about, when we do make a breakthrough, their stocks can, and shoot from 66 to 93 overnight less than three weeks ago. the hep-c pill or identix after catching a takeover bid from earning in and stay tuned for a

my personal view, between the cost cuts allergan can do and reasonably quality deal which david pyottt together in the past i think the company will stay independent. at any rate it will stay independent the inherent value of company organically will rise. david: thank you very much for being here, sanford bernstein. come back see us again. >> thank you for having me. liz: number unin his space. david: can they change the country's small business landscape? a fox business exclusive we'll speak with a woman that helped more than 900 entrepreneurs expand share businesses worldwide and create thousands of jobs around the world. liz: plus one major investment bank changing its tune on stocks in a good way. upping its s&p target by more than 150 points for the rest of this year. why? well of course we'll tell you coming up. ♪ hard it can be...how ...to breathe with copd? it can feel like this. copd includes chronic bronchitis and emphysema. spiriva is a once-daily inhaled... ...copd maintenance treatment... ...that helps open my airways for a full 24 hours. you know, spiriva helps me breat

it was interesting on the call, david pyott was asked, where are you going to make acquisitions? kind of strategic set, there really aren't opportunities. we're going to have to do a deal that's outside of the core. and we're going to have to find a new, you know, kind of area of competency to go pursue. first of all, those kind of acquisitions, allergan does not have a track record making major acquisitions outside its core discipline as opposed to adding on to something in, let's say, relevant to botox, for example. because they've got a lot of market share in their particular segment. so they can't do a synergistic acquisition. valeant is one of the most i've seen. it's a canadian company, has a much lower tax rate, and allergan as a standalone business can achieve that tax rate. you know, benefit. it's valeant light on the cost side, and it's strategically a tax efficiently, you know, weak otherwise. >> let me ask you one more question on this particular case. and then we can move on to herbalife. we have this complaint by valeant both u.s. and canadian regulators about what

. >>> and david pyott's first comments since the allergan takeover. that starts at 6:00 p.m.up of the services your vehicle needs. so prepare your car for any road trip by taking it to an expert ford technician. because no matter your destination good maintenance helps you save at the pump. get our multi-point inspection with a synthetic blend oil change, tire rotation, brake inspection and more for $29.95 or less. get a complete vehicle checkup only at your ford dealer. [ female announcer ] f provokes lust. ♪ it elicits pride... incites envy... ♪ ...and unleashes wrath. ♪ temptation comes in many heart-pounding forms. but only one letter. "f". the performance marque from lexus. there, and president obama in texas today feeling heat for what he's not doing. he's not visiting the border area where tens of thousands of illegal immigrants have entered the country creating an urgent humanitarian problem. jon harwood joins us with what the president is doing in texas in texas. >> the president remains under pressure in texas for that border crisis and at a hearing this morning, se

david pyott saying tax considerations certainly are on the table, but it's not something they're looking for sclus ofly, but they're keeping their options open. now the next thing we're looking at, next earnings coming up in the next few weeks and we should get a lot more info then. >> we've heard from shareholders, we have to do something. >> that's going to impact the entire industry. this is researching a whole use of money. >> that is the ultimate question, right? and i don't know enough about the subject to come up with the answer, but that seems to be the core debate. >> i think they think it's a dangerous thing to have happen when you come in and cut r&d. but when a company then comes in response and cuts costs, what analysts are saying is that he thinks they will come out and say told you so when they announce these cost cuts. >> if you don't do research, what do you do? >> you sell drugs that are already there. the whole argument is instead of the 100 that fail and one that makes it, you let universities or start ups or vc coming up with that and do all that legwork. then you se